SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Cellceutix Reports Its Very Novel Anti-Cancer Agent, Kevetrin, at Dana-Farber Cancer Institute for Start of Clinical Trials
Your Message